ArticleTargeted oncology2020

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.

Chi-Lu Chiang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.